CDK12 and neoplasm: We first analyzed RNA sequencing data from tumor samples collected prior to ICB treatment in 2 metastatic melanoma cohorts (22, 23) and found that low expression of CDK12/13 (bottom 20th percentile) was significantly associated with improved overall survival (Figure 1C).